Author:
Zhang Lihong,Yang Xia,Ming Zongjuan,Shi Jie,Lv Xin,Li Wei,Yuan Bo,Chen Yang,Liu Boxuan,Qin Kai,Liu Jiamin,Wei Qingbo,Gu Dejian,Chen Rongrong,Yuan Mingming,Cui Jean,Ou Sai-Hong Ignatius,Yang Shuanying
Subject
Cancer Research,Pulmonary and Respiratory Medicine,Oncology
Reference18 articles.
1. Deregulated EGFR signaling during lung cancer progression: mutations, amplicons, and autocrine loops;Gazdar;Cancer Prevent Res (Philadelphia, PA),2008
2. Examining treatment outcomes with erlotinib in patients with advanced non-small cell lung cancer whose tumors harbor uncommon EGFR mutations;Klughammer;J Thorac Oncol,2016
3. Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer;Wu;Clin Cancer Res,2011
4. Epidermal growth factor receptor mutations in lung cancer;Sharma;Nature Rev Cancer.,2007
5. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6;Yang;Lancet Oncol,2015
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献